IPO - NeuroSense Therapeutics Ltd.

Form Type: POS AM

Filing Date: 2025-04-11

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025031063

Filing Summary: NeuroSense Therapeutics Ltd. filed a Post-Effective Amendment No. 1 to Form F-1 Registration Statement with the SEC on April 11, 2025. This registration statement serves to update the prospectus related to the resale of up to 9,775,303 ordinary shares by the Selling Shareholder, YA II PN, LTD., as part of a Standby Equity Purchase Agreement signed on October 31, 2024. The company does not directly sell these securities nor will it receive proceeds from the sales by the Selling Shareholder. However, it could receive up to $30 million from sales of ordinary shares to YA under the Purchase Agreement over the next 36 months. The registration statement outlines the details of these offerings, legal implications, and the structure of the agreement, including underwriting fees. NeuroSense's lead therapeutic candidate, PrimeC, continues to progress through clinical trials, showing promise in treating ALS. The FDA's recent requirements for additional non-clinical data and the initiation of a Phase 3 study in the U.S. are also discussed as part of the forward-looking statements included in the filing. The document states that NeuroSense is defined as an emerging growth company, meaning it is eligible for reduced disclosure requirements, and includes cautionary notes regarding forward-looking statements. Finally, the filing emphasizes the uncertain nature of investments related to this registration due to various industry and operational risks.

Document Link: View Document